Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norleucine SCHEMBL14935842 | 1.00 | METAP1 (0.51) | METAP1SLC1A2SLC1A1SLC1A3SMN1; SMN2 | |
| Biphenyl SCHEMBL14247678 | 0.85 | SLC1A2 (0.50) | METAP1SLC1A2SLC1A1SLC1A3DDAH1 | |
| Lysine SCHEMBL2369399 | 0.84 | GSR (0.62) | DPP7DPP4DPP8DPP9FAP | |
| Lysine SCHEMBL2100363 | 0.84 | GSR (0.62) | DPP7DPP4DPP8DPP9FAP | |
| Norleucine SCHEMBL28461745 | 0.84 | SLC1A2 (0.49) | METAP1SLC1A2SLC1A1SLC1A3DDAH1 | |
| 2-Ethylhexanoic Acid SCHEMBL11502267 | 0.81 | CA2 (0.62) | SLC1A2SLC1A1SLC1A3SMN1; SMN2SIGMAR1 | |
| D-Glutamate SCHEMBL27975473 | 0.81 | GRM8 (0.60) | SLC1A2SLC1A1SLC1A3SMN1; SMN2DPP7 | |
| Glutamic Acid SCHEMBL27975498 | 0.81 | GRM8 (0.60) | SLC1A2SLC1A1SLC1A3SMN1; SMN2DPP7 | |
| SCHEMBL9825772 | 0.79 | SIGMAR1 (0.57) | METAP1SIGMAR1EPHX1DPP7DPP4 | |
| SCHEMBL27980206 | 0.79 | EPHX1 (0.49) | SMN1; SMN2EPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| EP-4578868-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4578867-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| CN-120202010-A | Ligand-oligonucleotide conjugates and linkers for use therewith | 上海京新生物医药有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4041249-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | The Scripps Research Institute (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-4041247-A1 | EUKARYOTIC SEMI-SYNTHETIC ORGANISMS | The Scripps Research Institute (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022170108-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF IN PREVENTION OF RADIATION INJURY | AILERON THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| US-20220243244-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | NATIONAL INSTITUTES OF HEALTH | 2022-08-04 | — | — | US | disclosed |
| US-20220226434-A1 | METHODS OF TREATING HYPERLIPIDEMIA CONDITIONS WITH NETRIN-1 COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-07-21 | — | — | US | disclosed |
| US-20220228148-A1 | EUKARYOTIC SEMI-SYNTHETIC ORGANISMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-21 | — | — | US | disclosed |
| US-20220133893-A1 | Therapeutic Nanomaterials | UNIVERSITY OF CONNECTICUT | 2022-05-05 | — | — | US | disclosed |
| WO-2022081721-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3983543-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | The Scripps Research Institute (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3976635-A1 | METHODS OF TREATING HYPERLIPIDEMIA CONDITIONS WITH NETRIN-1 COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | METAP1 2379/4885SLC1A2 2109/4885SLC1A1 1389/4885 |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MLX, BMX, ADM2 | METAP1 41/4885SLC1A2 336/4885SLC1A1 302/4885 |
| US-20220133893-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | METAP1 2379/4885SLC1A2 2109/4885SLC1A1 1389/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | METAP1 2030/4885SLC1A2 1557/4885SLC1A1 680/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | METAP1 3140/4885SLC1A2 708/4885SLC1A1 431/4885 |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MDN1, MLX, BMX | METAP1 17/4885SLC1A2 1665/4885SLC1A1 1666/4885 |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | RNGTT, TRMT1, OSGEP | METAP1 438/4885SLC1A2 737/4885SLC1A1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.